Venture capital firms Forbion Capital Partners, which spun out from Dutch bank ABN Amro at the end of 2006, and Edmond de Rothschild Investment Partners have co-led a series A financing round in newly-launched Allecra Therapeutics.
The €15m ($20m) commitment will support early clinical development of two new antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria. The investment is the first for Edmond de Rothschild Investment Partners’ BioDiscovery 4, its fourth fund dedicated to life sciences.
Formed earlier this…
